Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

(2014) Yi-Long Wu et al.   LANCET ONCOLOGY

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

(2014) Mark R. Gilbert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

(2014) Olivier L. Chinot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial

(2013) Mark R. Gilbert et al.   JOURNAL OF CLINICAL ONCOLOGY

NEURO/MEDICAL ONCOLOGY

(2013) P. Ambady et al.   NEURO-ONCOLOGY

A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors

(2012) John Marshall et al.   INVESTIGATIONAL NEW DRUGS

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

(2012) Vincent A Miller et al.   LANCET ONCOLOGY

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

(2012) James Chih-Hsin Yang et al.   LANCET ONCOLOGY

Standards of care for treatment of recurrent glioblastoma—are we there yet?

(2012) Michael Weller et al.   NEURO-ONCOLOGY

Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors

(2012) Igor Vivanco et al.   Cancer Discovery

Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers

(2011) Peter Stopfer et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib--A Phase II Trial

(2011) M. E. Hegi et al.   MOLECULAR CANCER THERAPEUTICS

A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy

(2011) J. J. Raizer et al.   NEURO-ONCOLOGY

A comprehensive study of the association between the EGFR and ERBB2 genes and glioma risk

(2010) Ulrika Andersson et al.   ACTA ONCOLOGICA

Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study

(2010) James R. Perry et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study

(2010) W. K. A. Yung et al.   NEURO-ONCOLOGY

A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation

(2009) Brian Thiessen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A Phase I Study of a 2-Day Lapatinib Chemosensitization Pulse Preceding Nanoparticle Albumin-Bound Paclitaxel for Advanced Solid Malignancies

(2009) A. J. Chien et al.   CLINICAL CANCER RESEARCH

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma

(2009) David A. Reardon et al.   JOURNAL OF NEURO-ONCOLOGY

Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma

(2009) Andrew D. Norden et al.   JOURNAL OF NEURO-ONCOLOGY

Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme

(2009) David M. Peereboom et al.   JOURNAL OF NEURO-ONCOLOGY

Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule

(2008) James R. Perry et al.   CANCER

A New Model for Prediction of Drug Distribution in Tumor and Normal Tissues: Pharmacokinetics of Temozolomide in Glioma Patients

(2008) L. Rosso et al.   CANCER RESEARCH

Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177

(2008) Paul D. Brown et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

(2008) Michael D. Prados et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma

(2008) J. F. de Groot et al.   JOURNAL OF NEURO-ONCOLOGY

A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)

(2008) Teri N. Kreisl et al.   JOURNAL OF NEURO-ONCOLOGY

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

(2008) D Li et al.   ONCOGENE